logo

PYXS

Pyxis Oncology·NASDAQ
--
--(--)
--
--(--)
6.14 / 10
Outperform

The stock's fundamentals show good quality (6.1/10). Favorable features: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, though challenges appear in Days sales outstanding. Analytical stance: positive.

Fundamental(6.14)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight17.04%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value-82.53
Score2/3
Weight1.46%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-1.87%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight13.59%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.60%
1M Return8.45%
PB-ROE
Value0.24
Score3/3
Weight18.43%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.36%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-82.53
Score2/3
Weight0.56%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight25.20%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.36%
1M Return8.41%
Is PYXS fundamentally strong?
  • PYXS scores 6.14/10 on fundamentals and holds a Discounted valuation at present. Backed by its -64.91% ROE, -3442.77% net margin, -0.96 P/E ratio, 1.36 P/B ratio, and -49.06% earnings growth, these metrics solidify its Outperform investment rating.